Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know
This disposition follows a staggering 500% one-year stock surge.
Overview
CEO Cameron Turtle reported a sale of 15,000 shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) in a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($95.51); post-transaction value based on the August 3 market close ($94.93).
Details
Spyre Therapeutics is a clinical-stage biotechnology firm with a market capitalization of $9.1 billion, demonstrating substantial investor confidence in its immunology-focused pipeline. The company is leveraging targeted monoclonal antibody technology to address inflammatory bowel disease, a chronic condition affecting millions of patients globally. Spyre is positioned within the competitive biotechnology landscape focused on precision immunotherapy development.
Source
Originally published at www.fool.com.